Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Lupin Pharmaceuticals' 250mg/5mL oral suspension generic version of Abbott's antibiotic cefdinir, marketed as Omnicef.
Subscribe to our email newsletter
Lupin has already received FDA approvals for the capsule form and the lower strength suspension, and with this approval the company can launch the entire product range, Mumbai-based Lupin said. Commercial shipment in the US has already commenced.
Omnicef had US sales of approximately $787 million for the 12-month period ending December 31, 2006, according to IMS Health. Cefdinir is indicated for the treatment of patients with mild to moderate infections caused by susceptible bacteria.
Vinita Gupta, president and managing director of Lupin Pharmaceuticals, said: “We are extremely pleased with the approval of the double strength suspension and look forward to offering the entire product line to our customers.”